Finland

Jaa

Valitse ajanjakso -
Avainsanat ( Aktiivinen)

Presentation of Biomarker Data at AACR 2022

Faron Pharmaceuticals Ltd (“Faron or Company”) Faron Announces Upcoming Presentation of Biomarker Analysis from Patients in MATINS Trial at AACR Annual Meeting 2022 · Analysis tested performance of baseline cytokine serum IFNy and TNFa levels to identify patients that experienced disease control following bexmarilimab treatment compared to those that did not · Patients with low baseline IFNy and TNFa levels found to experience significantly higher clinical benefit following bexmarilimab treatment · Bexmarilimab’s unique mode of action could serve as a catalyst for the

Faron Announces Presentation at ESMO Congress

Faron Pharmaceuticals Ltd. (“Faron”)  Faron Announces Presentation of Bexmarilimab Data From Ongoing MATINS Trial at the European Society for Medical Oncology Congress 2021   September 9, 2021 at 7:00 am BST / 9:00 am EEST TURKU, FINLAND / BOSTON, MA – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, today announces the presentation of updated data from the ongoing MATINS (Macrophage Antibody

Faron to Host KOL Webinar on the Potential of Clever-1 Receptor as a Target for Macrophage-Guided Immunotherapy on July 19, 2021

Faron Pharmaceuticals Oy (“Faron” or the “Company”) Faron to Host KOL Webinar on the Potential of Clever-1 Receptor as a Target for Macrophage-Guided Immunotherapy on July 19, 2021 TURKU, FINLAND / BOSTON, MA, July 12, 2021 – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, today announces that it will host a webinar entitled ‘Clever-1 as a target for macrophage-guided immunotherapy’ on Monday 19 July

Faron to Present at Oppenheimer Conference

Faron Pharmaceuticals Oy (“Faron” or the “Company”)   Faron Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference TURKU – FINLAND, March 11, 2021 – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON) , the clinical stage biopharmaceutical company, today announced that Dr. Markku Jalkanen, Chief Executive Officer of Faron Pharmaceuticals, will present at the virtual Oppenheimer 31st Annual Healthcare Conference on Thursday, March 18, 2021 at 10:40 a.m. ET. An audio webcast of the presentation will be available in the "Investors" section on Faron'

Faron to Present at H.C. Wainwright Conference

Faron Pharmaceuticals Oy (“Faron” or the “Company”) Faron Pharmaceuticals to Present at the Virtual H.C. Wainwright Global Life Sciences Conference TURKU – FINLAND, March 2, 2021 – Faron Pharmaceuticals Ltd (“Faron”) (LON: FARN), the clinical stage biopharmaceutical company, today announced that Dr. Markku Jalkanen, Chief Executive Officer of Faron Pharmaceuticals, will present in a pre-recorded presentation at the virtual H.C. Wainwright Global Life Sciences Conference that will be available on-demand starting Tuesday, March 9, 2021 at 7:00 a.m. ET. An audio webcast of the

Proposed Issue and Placing of Shares

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, SINGAPORE, HONG KONG OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE EU REGULATION 596/2014 ("MAR") AND ARTICLE 7 OF MAR AS INCORPORATED INTO UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL)

Faron to Present at H.C. Wainwright BioConnect

TURKU – FINLAND, January 4, 2021 – Faron Pharmaceuticals Ltd (“Faron”) (LON: FARN), the clinical stage biopharmaceutical company, today announced that Dr. Markku Jalkanen, Chief Executive Officer of Faron Pharmaceuticals, will present in a pre-recorded presentation at the virtual H.C. Wainwright BioConnect Conference that will be available on-demand starting Monday, January 11, 2021 at 6:00 a.m. ET. An audio webcast of the presentations will be available in the “Investors” section on Faron’s website at https://www.faron.com/investors ENDS For more information please contact:

Faron Pharmaceuticals to Participate in Upcoming Investor Conferences

TURKU – FINLAND, 23 November 2020  – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announced that management will participate in the following virtual investor conferences: · 32nd Annual Piper Sandler Virtual Healthcare ConferencePre-recorded fireside chat available on-demand starting Monday, 23 November 2020 at 10:00 a.m. ET  · 3rd Annual Evercore ISI HealthCONx ConferenceFireside Chat on Wednesday, 2 December 2020 at 8:25 a.m. ET Audio webcasts of the presentations will be available in the “Investors” section

Hakusi ei tuottanut tuloksia
Hakusi ei tuottanut enempää tuloksia
Takaisin alkuun

Tilaa